Regentys, a regenerative medicine company, announced it will partner with Cook Biotech Inc., collaborate to develop a novel treatment for ulcerative colitis.Cook Biotech will develop and manufacture Regentys’ licensed clinical product, ECMH Rectal Solution (Extracellular Matrix Hydrogel), which will be used in first-in-man clinical studies conducted by Regentys in 2018. As part of the partnership, Cook Biotech has become a stakeholder in Regentys.
Regentys Chief Business Officer Brian Andersen said “We have been working with the outstanding team at Cook Biotech for the last several months to complete the technology transfer of our product in order to scale our manufacturing for our clinical program, which will begin in the second half of 2018. Cook Biotech’s experience in the production of ECM is unmatched. They have successfully produced commercial products that have been used, and are currently being used, to treat patients worldwide for more than 20 years.”